Crossmark

The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis

Crossref DOI link: https://doi.org/10.1007/s12028-025-02217-0

Published Online: 2025-02-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Toker, Daniel

Chiang, Jeffrey N.

Vespa, Paul M.

Schnakers, Caroline

Monti, Martin M.
License Information

Text and Data Mining valid from 2025-02-04

Version of Record valid from 2025-02-04
More Information

Article History

Received: 30 July 2024

Accepted: 13 January 2025

First Online: 4 February 2025

Declarations

:

: The study did not require approval from an Institutional Review Board. We received confirmation from an administrator at the UCLA Institutional Review Board that our use of already de-identified patient data does not constitute human subjects research.

Document is current

Any future updates will be listed below